APA (7th ed.) Citation

Vigneswaran, H. T., Palsdottir, T., Micoli, C., Tilki, D., Lin, D., Cooperberg, M., . . . Eklund, M. (2026). Stockholm3 Versus Prostate-specific Antigen in Prostate Cancer Screening: 9-year Outcomes Demonstrating Improved Detection of Aggressive Cancers and Reduced Overdiagnosis from the STHLM3 Trial. European Urology, 89(1), 82. https://doi.org/10.1016/j.eururo.2025.10.001

Chicago Style (17th ed.) Citation

Vigneswaran, Hari T., et al. "Stockholm3 Versus Prostate-specific Antigen in Prostate Cancer Screening: 9-year Outcomes Demonstrating Improved Detection of Aggressive Cancers and Reduced Overdiagnosis from the STHLM3 Trial." European Urology 89, no. 1 (2026): 82. https://doi.org/10.1016/j.eururo.2025.10.001.

MLA (9th ed.) Citation

Vigneswaran, Hari T., et al. "Stockholm3 Versus Prostate-specific Antigen in Prostate Cancer Screening: 9-year Outcomes Demonstrating Improved Detection of Aggressive Cancers and Reduced Overdiagnosis from the STHLM3 Trial." European Urology, vol. 89, no. 1, 2026, p. 82, https://doi.org/10.1016/j.eururo.2025.10.001.